Search NTLA
Intellia Therapeutics, Inc.
NasdaqGM · CIK 1652130
Last close12.26
Daily change+0.14 (1.16%)
10 Years gain-26.54%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NTLA · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
42.9Momentum
0.0Acceleration
40.0Confidence
75.0Annual Revenue10
Quarterly Revenue36
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.1 / 25
Quality18.2 / 25
Capital Efficiency4.7 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 40.7863 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 15.4393 percentage points.
Heavy share dilution · HIGHDiluted share count increased 28.9662%.
Key Metrics
Revenue Growth TTM-17.68%OK
Revenue CAGR 3Y9.09%OK
Gross Marginn/aMISSING
Operating Margin-856.95%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-99.12%OK
Incremental Operating Margin 3Y-437.75%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y28.97%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $67.67M | n/a | -$440.99M | -$394.74M | -$395.87M | n/a | -651.67% | -584.98% | -141.63% | 108.38M |
| 2025 FY Dec 31, 2024 | $57.88M | n/a | -$534.26M | -$348.88M | -$354.66M | n/a | -923.1% | -612.78% | -206.7% | 98.85M |
| 2025 FY Dec 31, 2023 | $36.28M | n/a | -$515.29M | -$394.09M | -$408.07M | n/a | -1,420.51% | -1,124.94% | -450.04% | 88.77M |
| 2024 FY Dec 31, 2022 | $52.12M | n/a | -$458.16M | -$333.29M | -$346.85M | n/a | -879.04% | -665.46% | -216.4% | 76.97M |
| 2023 FY Dec 31, 2021 | $33.05M | n/a | -$267.85M | -$225.03M | -$237.79M | n/a | -810.37% | -719.41% | -191.27% | 70.89M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $50.73M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-337952, 0001193125-25-269680 |
| Revenue Growth TTM | -17.68% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-337952, 0001193125-25-269680 |
| Revenue CAGR 3Y | 9.09% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076550 |
| Revenue CAGR 5Y | 3.13% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076550 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-337952, 0001193125-25-269680 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -856.95% | Operating Income / Revenue | OK | 0001193125-26-337952, 0001193125-25-269680 |
| ROIC | -99.12% | NOPAT / Average Invested Capital | OK | 0001193125-26-337952, 0001193125-25-269680 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-337952 |
| Current Ratio | 6.65x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.38 | Revenue / Diluted Shares | OK | 0001193125-26-337952, 0001193125-25-269680 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-076550 |